Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00974610
Recruitment Status : Completed
First Posted : September 10, 2009
Last Update Posted : May 24, 2017
Information provided by (Responsible Party):
Cancer Trials Ireland

Brief Summary:

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

Condition or disease
Breast Cancer Colorectal Cancer Lung Cancer Melanoma (Skin) Pancreatic Cancer

Detailed Description:



  • To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups.


  • To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy.

OUTLINE: This is a multicenter study.

Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.

Study Type : Observational
Actual Enrollment : 803 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer
Study Start Date : August 2008
Actual Primary Completion Date : December 2015
Actual Study Completion Date : January 2017


Primary Outcome Measures :
  1. Detection of peptide and protein markers in serum [ Time Frame: Ongoing ]

Secondary Outcome Measures :
  1. Identification of the protein/peptide involved [ Time Frame: Ongoing ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
5 different tumour types


  • Diagnosis of 1 of the following advanced metastatic malignancies:

    • Malignant melanoma
    • Lung cancer
    • Breast cancer
    • Pancreatic carcinoma
    • Colorectal cancer
  • Advanced and/or metastatic disease
  • Hormone receptor status not specified


  • Menopausal status not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00974610

Cork University Hospital
Cork, Ireland
Mercy University Hospital
Cork, Ireland
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Dublin, Ireland, 24
St. Vincent's University Hospital
Dublin, Ireland, 4
Mater Misericordiae University Hospital
Dublin, Ireland, 7
St. James's Hospital
Dublin, Ireland, 8
Beaumont Hospital
Dublin, Ireland, 9
Mater Private Hospital
Dublin, Ireland
St Luke's Hospital
Dublin, Ireland
University College Hospital
Galway, Ireland
Letterkenny General Hospital
Letterkenny, Ireland
Mid-Western Cancer Centre at Mid-Western Regional Hospital
Limerick, Ireland, 0009
Waterford Regional Hospital
Waterford, Ireland
Sponsors and Collaborators
Cancer Trials Ireland
Principal Investigator: Martin Clynes National Institute for Cellular Biotechnology at Dublin City University

Responsible Party: Cancer Trials Ireland Identifier: NCT00974610     History of Changes
Other Study ID Numbers: CTRIAL-IE (ICORG) 07-12
First Posted: September 10, 2009    Key Record Dates
Last Update Posted: May 24, 2017
Last Verified: May 2017

Keywords provided by Cancer Trials Ireland:
stage IV melanoma
recurrent melanoma
stage IV non-small cell lung cancer
recurrent non-small cell lung cancer
extensive stage small cell lung cancer
recurrent small cell lung cancer
stage IV breast cancer
recurrent breast cancer
male breast cancer
stage III pancreatic cancer
stage IV pancreatic cancer
recurrent pancreatic cancer
stage IV colon cancer
recurrent colon cancer
stage IV rectal cancer
recurrent rectal cancer

Additional relevant MeSH terms:
Breast Neoplasms
Lung Neoplasms
Colorectal Neoplasms
Pancreatic Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases